We are Sorry, This Page doesn't Exist

Merck & Co Inc reported higher-than-expected second-quarter profit and revenue and raised its full-year earnings forecast on Tuesday, powered by strong demand for its blockbuster cancer immunotherapy Keytruda and vaccine sales......»»

Keytruda, Merck & Co., Inc. read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week hig.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 11) read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytr.....»»

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Incyte said its experimental cancer drug failed in a clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies......»»

(Reuters) - Drugmaker Merck & Co reported a better-than-expected first-quarter profit on Tuesday, helped by a more than 150 percent rise in sales of cancer drug Keytruda......»»

Sales of Pfizer's blockbuster drug Ibrance zoomed higher but missed forecasts. Sales of Merck's cancer drug Keytruda catapulted higher, but overall revenue disappointed Wall Street. Fred Katayama reports......»»

Merck & Co. Inc. said Monday its Keytruda drug showed positive results in a late-stage trial as a.....»»

Merck said long-term data from its cancer drug Keytruda showed promise in treating advanced melanoma patients. Fred Katayama reports......»»

Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phas.....»»

Drugmaker Merck & Co on Friday raised its full-year profit forecast after beating Wall Street estimates for quarterly profit as sales of blockbuster cancer drug Keytruda nearly doubled......»»

Merck’s adjusted earnings for the second quarter beat analysts’ expectations as sales of its cancer drug Keytruda increased 89%......»»

Merck & Co beat quarterly earnings estimates as sales of blockbuster drug Keytruda nearly doubled, but investors were disappointed after the drugmaker said it was unlikely to follow rival Eli Lilly in separating its animal health unit......»»

Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb's Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy......»»

Merck (MRK) beat estimates for earnings while missing the same for sales in third-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand tre.....»»